Melanie M Goens

Ms. Melanie M Goens

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
HHHoward Leigh Howard
Howard Leigh Howard
MGMelanie M Goens
Melanie M Goens
LSLeonardo Susta
Leonardo Susta
APAmi Patel
Ami Patel
SWSarah Wootton
Sarah Wootton
The development of anti-drug antibodies (ADAs) against therapeutic monoclonal antibodies (mAbs) poses significant challenges in the efficacy and safety of these treatments. ADAs can lead to adverse immune reactions, reduced drug efficacy, and increased clearance of therapeutic antibodies. This paper reviews the formation and mechanisms of ADAs, explores factors contributing to their development, and discusses potential strategies to mitigate ADA responses. Current and emerging strategies to reduce ADA formation include in silico and in vitro prediction tools, deimmunization techniques, antibody engineering, and various drug delivery methods. Additionally, novel approaches such as tolerogenic nanoparticles, oral tolerance, and in vivo delivery of therapeutic proteins via viral vectors and synthetic mRNA or DNA are explored. These strategies have the potential to enhance clinical outcomes of mAb therapies by minimizing immunogenicity and improving patient safety. Further research and innovation in this field are critical to overcoming the ongoing challenges of ADA responses in therapeutic antibody development.

8 August 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
ECElena Sonja Busuttil Campbell
Elena Sonja Busuttil Campbell
MGMelanie M Goens
Melanie M Goens
WCWenguang Cao
Wenguang Cao
BTBrad Thompson
Brad Thompson
LSLeonardo Susta
Leonardo Susta
SWSarah Wootton
Sarah Wootton
Monoclonal antibodies (mAbs) are important treatment modalities for preventing and treating infectious diseases, especially for those lacking prophylactic vaccines or effective therapies. Recent advances in mAb gene cloning from naturally infected or immunized individuals has led to the development of highly potent human mAbs against a wide range of human and animal pathogens. While effective, the serum half-lives of mAbs are quite variable, with single administrations usually resulting in short-term protection, requiring repeated doses to maintain therapeutic concentrations for extended periods of time. Moreover, due to their limited time in circulation, mAb therapies are rarely given prophylactically; instead, they are generally administered therapeutically after the onset of symptoms, thus preventing mortality, but not morbidity. Adeno-associated virus (AAV) vectors have an established record of high-efficiency in vivo gene transfer in a variety of animal models and humans. When delivered to post-mitotic tissues such as skeletal muscle, brain, and heart, or to organs in which cells turn over slowly, such as the liver and lungs, AAV vector genomes assume the form of episomal concatemers that direct transgene expression, often for the lifetime of the cell. Based on these attributes, many research groups have explored AAV-vectored delivery of highly potent mAb genes as a strategy to enable long-term expression of therapeutic mAbs directly in vivo following intramuscular or intranasal administration. However, clinical trials in humans and studies in nonhuman primates (NHPs) indicate that while AAVs are a powerful and promising platform for vectored immunoprophylaxis (VIP), further optimization is needed to decrease anti-drug antibody (ADA) and anti-capsid antibody responses, ultimately leading to increased serum transgene expression levels and improved therapeutic efficacy. The following review will summarize the current landscape of AAV VIP in NHP models, with an emphasis on vector and transgene design as well as general delivery system optimization. In addition, major obstacles to AAV VIP, along with implications for clinical translation, will be discussed.

19 November 2024 in Viruses
Verified
Journal Article
Open access
PDF file
MGMelanie M Goens
Melanie M Goens
HHHoward Leigh Howard
Howard Leigh Howard
BWBryce Warner
Bryce Warner
LSLeonardo Susta
Leonardo Susta
SWSarah Wootton
Sarah Wootton
The emergence and re-emergence of pathogens with pandemic potential has been a persistent issue throughout history. Recent decades have seen significant outbreaks of zoonotic viruses from members of the Coronaviridae, Filoviridae, Paramyxoviridae, Flaviviridae, and Togaviridae families, resulting in widespread infections. The continual emergence of zoonotic viral pathogens and associated infections highlights the need for prevention strategies and effective treatments. Central to this effort is the availability of suitable animal models, which are essential for understanding pathogenesis and assessing transmission dynamics. These animals are also critical for evaluating the safety and efficacy of novel vaccines or therapeutics and are essential in facilitating regulatory approval of new products. Rapid development of animal models is an integral aspect of pandemic response and preparedness; however, their establishment is fraught by several rate-limiting steps, including selection of a suitable species, the logistical challenges associated with sharing and disseminating transgenic animals (e.g., the time-intensive nature of breeding and maintaining colonies), the availability of technical expertise, as well as ethical and regulatory approvals. A method for the rapid development of relevant animal models that has recently gained traction, in large part due to the COVID-19 pandemic, is the use of gene therapy vectors to express human viral receptors in readily accessible laboratory animals to enable virus infection and development of clinical disease. These models can be developed rapidly on any genetic background, making mechanistic studies and accelerated evaluation of novel countermeasures possible. In this review, we will discuss important considerations for the effective development of animal models using viral vector approaches and review the current vector-based animal models for studying viral pathogenesis and evaluating prophylactic and therapeutic strategies, with an emphasis on models of SARS-CoV-2 infection based on the vectorized expression of human angiotensin-converting enzyme 2.

31 December 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
HHHoward Leigh Howard
Howard Leigh Howard
MGMelanie M Goens
Melanie M Goens
LSLeonardo Susta
Leonardo Susta
APAmi Patel
Ami Patel
SWSarah Wootton
Sarah Wootton
The development of anti-drug antibodies (ADAs) against therapeutic monoclonal antibodies (mAbs) poses significant challenges in the efficacy and safety of these treatments. ADAs can lead to adverse immune reactions, reduced drug efficacy, and increased clearance of therapeutic antibodies. This paper reviews the formation and mechanisms of ADAs, explores factors contributing to their development, and discusses potential strategies to mitigate ADA responses. Current and emerging strategies to reduce ADA formation include in silico and in vitro prediction tools, deimmunization techniques, antibody engineering, and various drug delivery methods. Additionally, novel approaches such as tolerogenic nanoparticles, oral tolerance, and in vivo delivery of therapeutic proteins via viral vectors and synthetic mRNA or DNA are explored. These strategies have the potential to enhance clinical outcomes of mAb therapies by minimizing immunogenicity and improving patient safety. Further research and innovation in this field are critical to overcoming the ongoing challenges of ADA responses in therapeutic antibody development.

27 September 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
MGMelanie M Goens
Melanie M Goens
HHHoward Leigh Howard
Howard Leigh Howard
BWBryce Warner
Bryce Warner
LSLeonardo Susta
Leonardo Susta
SWSarah Wootton
Sarah Wootton
The emergence and re-emergence of pathogens with pandemic potential has been a persistent issue throughout history. Recent decades have seen significant outbreaks of zoonotic viruses from members of the Coronaviridae, Filoviridae, Paramyxoviridae, Flaviviridae, and Togaviridae families, resulting in widespread infections. The continual emergence of zoonotic viral pathogens and associated infections highlights the need for prevention strategies and effective treatments. Central to this effort is the availability of suitable animal models, which are essential for understanding pathogenesis and assessment of transmission dynamics. These animals are also critical for evaluating the safety and efficacy of novel vaccines or therapeutics and are essential in facilitating regulatory approval of new products. Rapid development of animal models is an integral aspect of pandemic response and preparedness; however, their establishment is fraught by several rate-limiting steps, including selection of a suitable species, the logistical challenges associated with sharing and disseminating transgenic animals (e.g., the time-intensive nature of breeding and maintaining colonies), availability of technical expertise, as well as ethical and regulatory approvals. A method for rapid development of relevant animal models that has recently gained traction is the use of gene therapy vectors to express human viral receptors in readily accessible laboratory animals to enable virus infection and development of clinical disease. These models can be developed rapidly on any genetic background making mechanistic studies and accelerated evaluation of novel countermeasures possible. In this review, we will discuss important considerations for the effective development of animal models using viral vector approaches and review the current vector-based animal models for studying viral pathogenesis and evaluating prophylactic and therapeutic strategies.

26 March 2026 in BMC Biotechnology
Verified
Journal Article
Open access
PDF file
NZNicole Zielinska
Nicole Zielinska
HHHoward Leigh Howard
Howard Leigh Howard
BSBrenna A. Y. Stevens
Brenna A. Y. Stevens
MGMelanie M Goens
Melanie M Goens
CYCici Yang
Cici Yang
SWSarah Wootton
Sarah Wootton
Background: Precise control of transgene expression is essential for safe and effective AAV gene therapies. While capsid engineering has advanced tissue targeting, progress in developing regulatory elements that confine expression to specific tissues has lagged. This gap limits the ability to minimize off-target expression and associated safety risks, emphasizing the need for improved tissue-specific regulatory control. Results: Here, we evaluated 12 computationally designed tissue-specific promoters generated by Asimov’s proprietary algorithm. Promoters driving a heat-stable human placental alkaline phosphatase reporter gene were packaged into AAV6·2FF and administered to C57BL/6 mice intranasally, intramuscularly, and intraperitoneally. Expression was assessed macroscopically, microscopically, enzymatically and by vector genome quantification. We identified two strictly skeletal muscle-specific promoters independent of the AAV capsid or route of administration used, and two cardiac-specific promoters when administered intraperitoneally. Conclusions: These findings demonstrate that computational promoter design can yield elements with great strength and precision that enable safer and more targeted AAV gene therapies and offer a broadly applicable strategy for tissue-specific expression in treating various monogenic diseases.